TLR Therapeutics, Inc. has recently filed for an orphan drug status Phase II clinical trial with the US FDA on the treatment of myelodysplastic syndrome (MDS). About 30% of MDS cases advance to become cancer, specifically acute myeloid leukemia (AML). MDS is caused by the mutation of one or more genes that control development of blood cells. Patients with this condition usually present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Our lead drug is a therapeutic monoclonal antibody directed against the TLR2 receptor and has been in multiple clinical trials. The current global market sales of MDS drugs is USD 2.4 billion with a CAGR of approximately 10%. We expect to initiate these clinical trials in 03Q2023 and are in active discussions with corporate partners and investors. Our global joint venture partner is Neuramedy Co Ltd of Seoul, Korea and is supported multiple institutional investors as well as by the team at Berkeley Skydeck.
Company Details
- Employees
- 1
- Address
- 251 Little Falls Dr, Wilmington,delaware 19808,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://tlrtx.com/
- HQ
- Wilmington, Delaware
Tlr Therapeutics Questions
Tlr Therapeutics's website is https://tlrtx.com/
Tlr Therapeutics's LinkedIn profile is https://www.linkedin.com/company/tlr-therapeutics
Tlr Therapeutics has
1 employees.
View email and phone details for 1
employees at Tlr Therapeutics.
Tlr Therapeutics's industry is
Pharmaceutical Manufacturing
Tlr Therapeutics's top competitors are
Alkemio,
The Hurd Co.,
T-Robotics,
Taltrics,
Partner Element,
Mycro Harvest,
Propulsionai,
Firstread,
Jellie Ai,
Deeli Ai.
Tlr Therapeutics's categories are Pharmaceutical Manufacturing
